# Momelotinib in Transfusion-Dependent Adults With Primary Myelofibrosis (PMF) or Post-polycythemia Vera or Post-essential Thrombocythemia Myelofibrosis (Post-PV/ET MF)

> **NCT02515630** · PHASE2 · COMPLETED · sponsor: **Sierra Oncology LLC - a GSK company** · enrollment: 41 (actual)

## Conditions studied

- Primary Myelofibrosis (PMF)
- Post-polycythemia Vera (Post-PV) Myelofibrosis
- Postessential Thrombocythemia (Post-ET) Myelofibrosis

## Interventions

- **DRUG:** MMB

## Key facts

- **NCT ID:** NCT02515630
- **Lead sponsor:** Sierra Oncology LLC - a GSK company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-01-29
- **Primary completion:** 2017-07-18
- **Final completion:** 2017-08-15
- **Target enrollment:** 41 (ACTUAL)
- **Last updated:** 2023-06-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02515630

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02515630, "Momelotinib in Transfusion-Dependent Adults With Primary Myelofibrosis (PMF) or Post-polycythemia Vera or Post-essential Thrombocythemia Myelofibrosis (Post-PV/ET MF)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02515630. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*